hVIVO (LON:HVO) Stock Price Passes Above 50 Day Moving Average – Here’s Why

hVIVO plc (LON:HVO)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 7.56 and traded as high as GBX 8.30. hVIVO shares last traded at GBX 7.88, with a volume of 2,097,438 shares.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Stifel Nicolaus restated a “hold” rating and set a GBX 10 target price on shares of hVIVO in a report on Thursday, May 7th. Shore Capital Group restated a “buy” rating on shares of hVIVO in a research report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 15.

hVIVO Stock Down 2.8%

The firm has a market cap of £54.21 million, a P/E ratio of -9.05 and a beta of 1.69. The business’s fifty day moving average price is GBX 7.56 and its two-hundred day moving average price is GBX 6.97. The company has a current ratio of 1.63, a quick ratio of 1.16 and a debt-to-equity ratio of 38.75.

hVIVO (LON:HVO) last posted its earnings results on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. The firm had revenue of GBX 4,677 million during the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. As a group, equities research analysts anticipate that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Transactions at hVIVO

In related news, insider Brendan Buckley sold 2,017,000 shares of hVIVO stock in a transaction dated Friday, April 24th. The shares were sold at an average price of GBX 9, for a total transaction of £181,530. 5.24% of the stock is owned by corporate insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.